Opus Genetics Receives FDA Approval For Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% To Treat Presbyopia In Adults

Loading news article.

Opus Genetics Receives FDA Approval For Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% To Treat Presbyopia In Adults | WAPE

Opus Genetics Receives FDA Approval For Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% To Treat Presbyopia In Adults

Article summary

Related companies

Analyzed by WAPE AI.

Comments —